^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Erbitux (cetuximab)

    i
    Company:
    BMS, EMD Serono, Eli Lilly
    Drug class:
    EGFR inhibitor
    Related drugs:
    Apply
    sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC (NCT04091867)
    Phase 1
    University of Colorado, Denver
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    01/06/2020
    Primary completion :
    05/14/2021
    Completion :
    10/25/2022
    EPHB4
    |
    EGFR expression • CDKN2A negative
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • sEphB4-HSA
    Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (ECOG-ACRIN EA3202) (NCT05063552)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2023
    Primary completion :
    12/15/2027
    Completion :
    12/15/2027
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • docetaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/04/2024
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    KRAS
    |
    Erbitux (cetuximab) • irinotecan • Zynyz (retifanlimab-dlwr)
    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) (NCT05253651)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/24/2022
    Primary completion :
    04/03/2026
    Completion :
    07/27/2029
    HER-2
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium
    A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) (NCT06599502)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/18/2024
    Primary completion :
    01/20/2028
    Completion :
    01/20/2028
    KRAS
    |
    KRAS mutation • KRAS G12D
    |
    Erbitux (cetuximab)
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) (NCT04607421)
    Phase 3
    Pfizer
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/21/2020
    Primary completion :
    01/06/2025
    Completion :
    12/24/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Zirabev (bevacizumab-bvzr) • Khapzory (levoleucovorin) • levoleucovorin calcium
    Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (RTOG 1216) (NCT01810913)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/22/2013
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    EGFR • CD4
    |
    CDKN2A negative
    |
    Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • docetaxel • Datalai (cetuximab biosimilar)
    A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06818812)
    Phase 1
    Incyte Corporation
    Not yet recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/10/2025
    Primary completion :
    03/27/2027
    Completion :
    03/27/2027
    KRAS
    |
    Erbitux (cetuximab) • irinotecan
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (NCT06011772)
    Phase 1
    Roswell Park Cancer Institute
    Suspended
    Last update posted :
    02/19/2025
    Initiation :
    12/04/2023
    Primary completion :
    12/04/2025
    Completion :
    12/04/2026
    KRAS • BRAF • RAS
    |
    BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer (NCT06833866)
    Phase 1
    The Methodist Hospital Research Institute
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/04/2024
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    CD8 • CD4
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    Avelumab with or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer (NCT03944941)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/17/2019
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    PD-L1 • CD4
    |
    Erbitux (cetuximab) • Bavencio (avelumab)
    A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (NCT05249426)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    04/12/2022
    Primary completion :
    07/16/2024
    Completion :
    08/02/2025
    SIRPA
    |
    Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (NCT06102902)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2024
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRAF
    |
    BRAF V600E
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694
    Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (NCT03290937)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2017
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    MSI
    |
    MSI-H/dMMR • RAS mutation
    |
    Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (GO42144) (NCT04449874)
    Phase 1
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/29/2020
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • erlotinib • divarasib (RG6330) • Itovebi (inavolisib) • migoprotafib (RLY-1971)
    Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) (NCT06640166)
    Phase 2
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    06/03/2024
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
    Phase 1/2
    Erasca, Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/20/2021
    Primary completion :
    08/01/2025
    Completion :
    12/01/2025
    KRAS • BRAF • NRAS
    |
    BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
    |
    Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
    Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) (NCT04793958)
    Phase 3
    Mirati Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/30/2026
    Completion :
    01/30/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium
    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283)
    Phase 1
    Merck Sharp & Dohme LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/17/2021
    Primary completion :
    08/19/2027
    Completion :
    08/19/2027
    PD-L1 • KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • MK-1084
    QTX3046 in Patients with KRAS G12D Mutations (NCT06428500)
    Phase 1
    Quanta Therapeutics
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/30/2024
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    KRAS
    |
    Erbitux (cetuximab) • QTX3046
    A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2) (NCT06662786)
    Phase 3
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/18/2024
    Primary completion :
    12/15/2028
    Completion :
    12/15/2032
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (NCT05355701)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/05/2022
    Primary completion :
    09/23/2026
    Completion :
    03/26/2028
    BRAF
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • PF-07799933
    TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (TTX-080-001) (NCT04485013)
    Phase 1
    Tizona Therapeutics, Inc
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/14/2020
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    BRAF
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (NCT05674526)
    Phase 1
    Wugen, Inc.
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    05/21/2024
    Primary completion :
    09/30/2025
    Completion :
    06/01/2026
    EGFR • BRAF
    |
    BRAF V600E • BRAF V600 • EGFR expression • RAS mutation
    |
    Erbitux (cetuximab) • WU-NK-101
    A Study of ASP3082 in Adults With Advanced Solid Tumors (3082-CL-0101) (NCT05382559)
    Phase 1
    Astellas Pharma Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/08/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • ASP3082
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (NCT06447662)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/27/2024
    Primary completion :
    07/30/2027
    Completion :
    07/29/2028
    KRAS
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium
    A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene (NCT06704724)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    12/10/2024
    Primary completion :
    01/30/2028
    Completion :
    01/29/2029
    KRAS
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • sasanlimab (PF-06801591) • PF-07284892
    A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3) (NCT06750094)
    Phase 3
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/12/2024
    Primary completion :
    12/15/2027
    Completion :
    04/13/2029
    BRAF
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Rybrevant (amivantamab-vmjw) • leucovorin calcium • levoleucovorin calcium
    ZN-c3 in Adult Participants With Metastatic Colorectal Cancer (ZN-c3-016) (NCT05743036)
    Phase 1
    K-Group, Beta, Inc., a wholly owned subsidiary ...
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    02/27/2023
    Primary completion :
    07/16/2024
    Completion :
    09/25/2026
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • azenosertib (ZN-c3)
    Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa) (NCT01878422)
    Phase 3
    Istituto Scientifico Romagnolo per lo Studio e ...
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    11/01/2007
    Primary completion :
    03/01/2014
    Completion :
    06/11/2016
    KRAS
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (NCT02671435)
    Phase 1/2
    MedImmune LLC
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    02/22/2016
    Primary completion :
    10/26/2021
    Completion :
    09/01/2025
    BRAF
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • monalizumab (IPH2201)
    PhII ICb With/Without Erbitux in MBC Pts (CA225200) (NCT00248287)
    Phase 2
    US Oncology Research
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    07/28/2005
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    EGFR • HER-2 • PGR
    |
    HER-2 negative
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • irinotecan
    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (NCT04966481)
    Phase 3
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    04/06/2022
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    CDKN2A
    |
    CDKN2A negative
    |
    Erbitux (cetuximab) • Ibrance (palbociclib)
    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
    Phase 1/2
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    07/19/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
    A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01) (NCT06586515)
    Phase 1
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    09/12/2024
    Primary completion :
    03/01/2029
    Completion :
    03/01/2029
    KRAS
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (NCT06607185)
    Phase 1
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    10/21/2024
    Primary completion :
    01/01/2030
    Completion :
    01/01/2030
    KRAS
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET) (NCT06578559)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    01/23/2025
    Initiation :
    07/23/2024
    Primary completion :
    08/01/2026
    Completion :
    04/01/2027
    BRAF
    |
    Erbitux (cetuximab) • Braftovi (encorafenib)
    Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer (NCT06776757)
    Phase 1/2
    Cancer Hospital Chinese Academy of Medical Scie...
    Recruiting
    Last update posted :
    01/15/2025
    Initiation :
    12/25/2023
    Primary completion :
    06/25/2025
    Completion :
    12/25/2025
    BRAF
    |
    Erbitux (cetuximab) • 5-fluorouracil • Tyvyt (sintilimab) • oxaliplatin • irinotecan • leucovorin calcium
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (SWOG S1613) (NCT03365882)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    11/27/2017
    Primary completion :
    11/01/2022
    Completion :
    11/30/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    Irinotecan Liposomes Combined With Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer (VICPROIRI) (NCT06763029)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    01/13/2025
    Initiation :
    01/02/2025
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    BRAF
    |
    Erbitux (cetuximab)
    Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) (NCT06728618)
    Phase 2
    Shanghai Zhongshan Hospital
    Not yet recruiting
    Last update posted :
    12/11/2024
    Initiation :
    12/01/2024
    Primary completion :
    05/01/2026
    Completion :
    03/01/2028
    TMB • MSI
    |
    PD-L1 expression
    |
    Erbitux (cetuximab) • cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer (NCT05722327)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/09/2024
    Initiation :
    12/06/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2027
    KRAS • UGT1A1
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • irinotecan • Krazati (adagrasib)